Research progress of phosphodiesterase 5 in heart failure

Abstract

Phosphodiesterase 5 (PDE5), a cyclic guanosine monophosphate (cGMP)-specific hydrolase, is targets cGMP produced by soluble guanosine cyclase (sGC) that is activated by nitric oxide (NO). It catalyzes the hydrolysis of the phosphodiester bond in cGMP and converts cGMP to the inactive 5′-GMP form. The cGMP-PKG axis dysfunction is one of the main causes of heart failure (HF) and causes cardiac remodeling. However, the clinical efficacy of PDE5 inhibitors in the treatment of heart failure is controversial. This paper summarizes the mechanism and research progress of PDE5 in heart failure in recent years, which has important significance for the clinical application of PDE5 in heart failure.

Keywords

• heart failure|phosphodiesterase 5|phosphodiesterase inhibitor|cyclic guanosine monophosphate